Assignee
BERGENBIO ASA
NO·10 granted patents·12 pending applications·19 citations·filing 2013–2024
Top patents by PatentIndex Score
22 records- 0190US9975954B2Anti-Axl antibodiesBERGENBIO ASA·Filed 2015·Granted May 22, 2018·8 cites·27 claims
- 0284US9975953B2Anti-Axl antibodiesBERGENBIO ASA·Filed 2015·Granted May 22, 2018·7 cites·26 claims
- 0377US11035008B2Biomarkers for cancerBERGENBIO ASA·Filed 2016·Granted Jun 15, 2021·2 cites·10 claims
- 0475US2024277707A1Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic VirusBERGENBIO ASA·Filed 2024·Application pending·0 cites
- 0570US2023149397A1Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic VirusBERGENBIO ASA·Filed 2022·Application pending·0 cites
- 0670US2022185897A1Anti-axl antibodiesBERGENBIO ASA·Filed 2021·Application pending·0 cites
- 0769US10336702B2Pharmaceutically active compoundsBERGENBIO ASA·Filed 2015·Granted Jul 2, 2019·1 cites·28 claims
- 0865US11186643B2Anti-Axl antibodiesBERGENBIO ASA·Filed 2018·Granted Nov 30, 2021·0 cites·16 claims
- 0964US2022073625A1Humanized anti-axl antibodiesBERGENBIO ASA·Filed 2021·Application pending·0 cites
- 1063US10766861B2Pharmaceutically active compoundsBERGENBIO ASA·Filed 2019·Granted Sep 8, 2020·0 cites·9 claims
- 1162US2021070708A1Pharmaceutically Active CompoundsBERGENBIO ASA·Filed 2020·Application pending·0 cites
- 1259US2024173403A1Combination of AXL Antibodies and ACE Inhibitors in the Treatment of FibrosisBERGENBIO ASA·Filed 2022·Application pending·0 cites
- 1358US11534440B2Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virusBERGENBIO ASA·Filed 2020·Granted Dec 27, 2022·0 cites·18 claims
- 1458US11059893B2Humanized anti-AXL antibodiesBERGENBIO ASA·Filed 2016·Granted Jul 13, 2021·0 cites·11 claims
- 1558US9783801B2Methods for creating and identifying functional RNA interference elementsBERGENBIO ASA·Filed 2013·Granted Oct 10, 2017·0 cites·17 claims
- 1655US2023372337A1Combination Therapy Comprising an AXL InhibitorBERGENBIO ASA·Filed 2021·Application pending·0 cites
- 1754US2018153888A1Combination therapy with axl inhibitor and immune checkpoint modulator or oncolytic virusBERGENBIO ASA·Filed 2016·Application pending·0 cites
- 1852US10317405B2Methods of detecting Akt3 and administering Ax1 inhibitorBERGENBIO ASA·Filed 2013·Granted Jun 11, 2019·1 cites·14 claims
- 1949US2023151100A1Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint ModulatorBERGENBIO ASA·Filed 2021·Application pending·0 cites
- 2048US2023250169A1AXL Inhibitors for Antiviral TherapyBERGENBIO ASA·Filed 2021·Application pending·0 cites
- 2146US2021215697A1Serum BiomarkersBERGENBIO ASA·Filed 2019·Application pending·0 cites
- 2235US2020072839A1MethodBERGENBIO ASA·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when BERGENBIO ASA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →